Gaboxadol is known to produce auditory hallucination, a auditory effect. Auditory hallucination is the perception of sounds that have no external source — hearing music, voices, environmental noises, or abstract sonic phenomena that exist entirely within the mind. These range from faint, ambiguous whispers at the edge of perception to fully formed, complex musical compositions or conversational speech that can feel completely real and externally sourced.
From a first-person perspective, auditory hallucinations manifest as sounds that feel genuinely external — as though they originate from somewhere in the physical environment — despite having no corresponding source. One may hear faint music playing from another room, indistinct conversational murmuring, environmental sounds like running water or wind, or entirely novel sonic phenomena such as buzzing, chiming, or crystalline tones. At higher intensities, full musical compositions may be perceived with remarkable complexity and fidelity, sometimes in genres or styles the listener has never heard before. Voices may speak coherent sentences, sometimes addressing the user directly, though insight is usually maintained that these are drug-induced.
At threshold levels, auditory hallucinations present as vague, ambiguous sounds — one might question whether a faint sound was real or imagined. At light to moderate intensities, the hallucinations become more distinct: identifiable snippets of music, recognizable whispered words, or phantom environmental sounds like doorbells or phone notifications. At strong doses, fully formed auditory experiences emerge — entire songs with lyrics, complex conversations, or rich environmental soundscapes that are indistinguishable from reality until one actively questions their origin. At overwhelming levels, the hallucinated audio can completely dominate the perceptual field, making it difficult to distinguish real from imagined sound.
Musical hallucinations involve hearing melodies, harmonies, or complete compositions, often novel and not drawn from memory.Verbal hallucinations consist of hearing words or sentences — these may be fragments, gibberish, or coherent speech.Environmental hallucinations replicate familiar ambient sounds (rain, traffic, appliances).Abstract sonic hallucinations produce sounds without clear real-world analogues — geometric buzzing, fractal tones, or sounds that seem to have visual or spatial properties. Auditory hallucinations can beopen-eye (perceived as external) orclosed-eye (perceived as internal, mind's-ear phenomena).
Auditory hallucinations arise from spontaneous activation of auditory cortical areas in the absence of corresponding external stimuli. Serotonergic psychedelics facilitate this through 5-HT2A agonism, which increases spontaneous neural firing in auditory association cortex and disrupts the brain's ability to distinguish internally generated signals from external input. Dissociatives produce auditory hallucinations through NMDA antagonism, which impairs sensory gating mechanisms and can lead to disinhibited firing in temporal lobe auditory regions. Deliriants such as diphenhydramine produce particularly vivid and realistic auditory hallucinations through muscarinic acetylcholine receptor antagonism, which profoundly disrupts the neurotransmitter systems involved in reality testing.
Auditory hallucinations occur across many substance classes but with qualitatively different characters. Psychedelics (LSD, psilocybin, DMT) tend to produce musical and abstract auditory hallucinations, often pleasant and complex.Dissociatives (ketamine, DXM, PCP) can generate immersive sonic environments, particularly during dissociative holes.Deliriants (diphenhydramine, datura) produce the most realistic and often disturbing auditory hallucinations — convincing phantom conversations and environmental sounds that are difficult to distinguish from reality.Cannabis at high doses, particularly edibles, can produce mild auditory hallucinations.Stimulant psychosis from prolonged use of amphetamines or cocaine can generate persecutory auditory hallucinations.
While psychedelic auditory hallucinations are generally benign and often enjoyable, deliriant-induced auditory hallucinations deserve serious caution — they can be indistinguishable from reality and may provoke dangerous behavioral responses. Stimulant-induced auditory hallucinations (especially persecutory voices) are a sign of psychosis and indicate a medical emergency requiring cessation of use and professional help. Individuals with a personal or family history of schizophrenia or psychotic disorders should exercise extreme caution with any substance that produces auditory hallucinations, as these effects may trigger or exacerbate underlying conditions. If hallucinated voices become commanding or frightening, this is a sign to seek immediate support.
Auditory hallucination can manifest at varying intensities depending on the dose of Gaboxadol and individual sensitivity. The following levels describe the typical progression of this effect.
Vague, ambiguous sounds at the edge of perception — faint whispers, phantom notification sounds, or barely audible music that one cannot be sure is real.
Identifiable sounds with no source — distinct musical snippets, recognizable words or phrases, phantom environmental sounds like a ringing phone.
Clear and detailed auditory hallucinations — full melodies, conversational fragments, or rich environmental soundscapes; one can usually still distinguish them from reality.
Complex, vivid auditory experiences — entire songs with lyrics, coherent conversations, or immersive sonic environments that are difficult to distinguish from real sounds.
Complete auditory hallucination dominance — the hallucinated soundscape is indistinguishable from reality; real and imagined sounds merge into a single perceptual stream.
Pharmacodynamics Gaboxadol acts as a potent and selective GABAA receptor partial agonist. In contrast to GABAA receptor positive allosteric modulators like benzodiazepines, Z drugs, barbiturates, and alcohol, gaboxadol is an agonist of the orthosteric site of the GABAA receptor and the same site that the neurotransmitter γ-aminobutyric acid binds to and activates. Whereas the related GABAA receptor agonist muscimol is a highly potent partial agonist of the GABAA-ρ receptor (GABAC receptor), gaboxadol is a moderately potent antagonist of this receptor. Unlike muscimol, it is not also a GABA reuptake inhibitor to any extent, and it does not inhibit the enzyme GABA transaminase (GABA-T).
The drug shows functional selectivity at the GABAA receptor relative to GABA itself, activating GABAA receptors of different α subunit compositions with varying efficacies. Its EmaxTooltip maximal efficacy values at GABAA receptors were approximately 71% at α1 subunit-containing receptors, 98% at α2 subunit-containing receptors, 54% at α3 subunit-containing receptors, 40% at α4 subunit-containing receptors, 99% at α5 subunit-containing receptors, and 96% at α6 subunit-containing receptors. Moreover, gaboxadol has been found to act as a supra-maximal agonist at α4β3δ subunit-containing GABAA receptors, low-potency agonist at α1β3γ2 subunit-containing receptors, and partial agonist at α4β3γ subunit-containing receptors. Its affinity for extrasynaptic α4β3δ subunit-containing GABAA receptors is 10-fold greater than for other subtypes. Gaboxadol has a unique affinity for extrasynaptic α4β3δ subunit-containing GABAA receptors, which mediate tonic inhibition and are typically activated by ambient, low levels of GABA in the extrasynaptic space. The supra-maximal efficacy of gabaxadol at α4β3δ subunit-containing GABAA receptors has been attributed to an increase in the duration and frequency of channel openings relative to GABA. Mice with the GABAA receptor δ subunit knocked out are unresponsive to the hypnotic effects of gaboxadol. Because of its preferential agonism of extrasynaptic GABAA receptors, gaboxadol has been referred to as a "selective extrasynaptic GABAA agonist" or "SEGA". In contrast to gaboxadol, benzodiazepines and nonbenzodiazepines do not activate δ subunit-containing GABAA receptors. On the other hand, alcohol is known to selectively potentiate δ subunit-containing extrasynaptic GABAA receptors analogously to gaboxadol. In addition, neurosteroids and propofol act on extrasynaptic δ subunit-containing GABAA receptors.
Gaboxadol shows 25- to 40-fold lower potency as a GABAA receptor agonist than muscimol in in vitro studies. Compared to muscimol, gaboxadol binds less potently to α4β3δ subunit-containing GABAA receptors (EC50Tooltip half-maximal effective concentration = 0.2μM vs. 13μM), but is capable of evoking a greater maximum response (EmaxTooltip maximal efficacy = 120% vs. 224%). Although gaboxadol is far less potent than muscimol in vitro, it is only about 3times less potency than muscimol in rodents in vivo. This is attributed mainly to gaboxadol's much greater ability to cross the blood–brain barrier than muscimol. However, it appears to be due to gaboxadol levels being several-fold higher than levels of muscimol with systemic administration of the same doses as well. Gaboxadol is also more selective than muscimol and has been said by Povl Krogsgaard-Larsen to be much less toxic in comparison.
In animals, gaboxadol has been found to produce sedation, hypnotic effects, motor impairment, muscle relaxation, hypolocomotion, anxiolytic-like effects, antidepressant-like effects, analgesic effects, and anticonvulsant effects. In rodent drug discrimination studies, gaboxadol has been found to fully generalize with muscimol. However, gaboxadol, GABAA receptor positive allosteric modulators like benzodiazepines and Z drugs, and the GABA reuptake inhibitor tiagabine all do not generalize between each other, suggesting that their interoceptive effects are different. Similarly, gaboxadol did not generalize with the neurosteroid pregnanolone. On the other hand, gaboxadol has shown partial generalization with the barbiturate pentobarbital. Gaboxadol does not produce self-administration or conditioned place preference in rodents or baboons, suggesting that it lacks rewarding or reinforcing effects and has low addictive potential. This is in contrast to benzodiazepines like diazepam.
Pharmacokinetics
Absorption The absorption of gaboxadol is rapid and almost complete with oral administration (83–96%). It is a zwitterionic compound and its absorption involves active transport via intestinal transporters such as the proton-coupled amino acid transporter 1 (PAT-1). Coadministration of PAT-1 inhibitors like tryptophan or 5-hydroxytryptophan (5-HTP) has been found to decrease the absorptive permeability of gaboxadol by 53 to 89%. However, they may simply delay the absorption of gaboxadol and decrease peak levels. In contrast to the case of the PAT-1, the drug is not a substrate of the proton-coupled di-/tripeptide transporter (PepT-1). Peak levels of gaboxadol are reached 15 to 60minutes after an oral dose.
Distribution The distribution of gaboxadol has been studied in rodents. It penetrates the blood–brain barrier and hence is centrally active unlike γ-aminobutyric acid (GABA). The drug enters the brain in amounts that are 30 to 100times higher than those of muscimol given at the same dose in rodents and hence shows greater blood–brain barrier permeability in comparison. In addition, whereas 90% of the muscimol in the brain is in the form of metabolites in rodents, 80% of the gaboxadol in the brain is in unchanged form. It is unknown which transporters are involved in the transport of gaboxadol across the blood–brain barrier or if it simply crosses into the brain via passive diffusion, although the latter may be more likely. The drug is distributed unevenly in the brain in rodents. The plasma protein binding of gaboxadol in humans is very low at less than 2%.
Metabolism Gaboxadol is metabolized by O-glucuronidation mainly via the enzyme UGT1A9 into gaboxadol-O-glucuronide. To a lesser extent, UGT1A6, UGT1A7, and UGT1A8 also catalyze the formation of this metabolite. Unlike muscimol, gaboxadol is not a substrate for GABA transaminase (GABA-T) and does not undergo metabolic transamination. It is said to be more resistant to metabolism than muscimol. Gaboxadol-O-glucuronide is the only metabolite of gaboxadol formed in significant amounts. Gaboxadol is not metabolized by the cytochrome P450 system.
Elimination Gaboxadol is excreted in urine (83–94%) mainly unchanged and partially as gaboxadol-O-glucuronide (34%). It is taken up from blood into the kidneys via the organic anion transporter OAT1 (SLC22A6), while the glucuronide is effluxed into urine via the multidrug resistance protein MRP4 (ABCC4). The drug has an elimination half-life in humans of 1.5 to 2.0hours. Twohours following attainment of peak concentrations, levels of gaboxadol are reduced by about 50% in humans. In rodents, the half-life of gaboxadol was about twice as long as that of muscimol. In people with severe renal impairment, circulating levels of gaboxadol were increased by 5-fold, and the renal clearance of gaboxadol was decreased by 34% while that of gaboxadol-O-glucuronide was decreased by 50%.
Gaboxadol can be administered via oral. The route of administration can influence both the onset and intensity of auditory hallucination.
The intensity of auditory hallucination depends heavily on the dose of Gaboxadol. Effects like auditory hallucination are typically reported at common to strong doses. Below is the full dosage chart for Gaboxadol.
Warning
Realistic auditory hallucinations, especially from deliriants or stimulant psychosis, can be indistinguishable from reality and may prompt dangerous behavior. Hearing commanding or persecutory voices is a sign of acute psychosis requiring immediate medical attention. Individuals with a history of psychotic disorders should avoid substances that produce this effect.
Yes. Auditory hallucination is a documented auditory effect of Gaboxadol. Auditory hallucination is the perception of sounds that have no external source — hearing music, voices, environmental noises, or abstract sonic phenomena that exist entirely within the mind. These range from faint, ambiguous whispers at the edge of perception to fully formed, complex musical compositions or conversational speech that can feel completely real and externally sourced.
Effects like auditory hallucination are typically reported at common doses and above. A common oral dose of Gaboxadol is 15–30 mg.
Other substances documented to produce auditory hallucination include Diphenhydramine, Datura, Dextromethorphan, Methamphetamine, Ibogaine, and 35 more.